HealthKart, a health supplement platform based in Gurugram, has successfully concluded a secondary funding round worth $153 million. The funding round was led by ChrysCapital and Motilal Oswal Alternates, with participation from Neo Group and existing investor A91 Partners.
The funds were used to purchase shares from early investors and stakeholders, providing liquidity without the issuance of new shares. This funding round has increased HealthKart's valuation to approximately $500 million, up from its previous valuation of $370 million in 2022.
HealthKart's investor roster includes Peak XV, Temasek, Sofina, Kae Capital, Intel Capital, and wealth manager IIFL. As part of this transaction, the company also announced a $6.5 million Employee Stock Ownership Plan (ESOP) buyback.